Drugs / MCLA-145
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03922204 | May 2019 → Nov 2024 | B-cell neoplasm, cancer of unknown primary site | Merus B.V. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-01-25 | Incyte Corporation | Incyte Provides Update on Parsaclisib and MCLA-145 incyte.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MCLA-145 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03922204 ↗ |
| Modality | Monoclonal antibody | “full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137” NCT03922204 ↗ |
| Route | Intravenous | “receive intravenous infusion of MCLA-145” NCT03922204 ↗ |